A Phase 3 interventional study of Whole Breast Irradiation (WBI) and Partial Breast Irradiation (PBI) in Breast Neoplasm Female, Radiotherapy and Cosmetic Outcome, sponsored by Ontario Clinical Oncology Group (OCOG). Recruiting at 31 sites in 2 countries. Open to female participants aged 50 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-09-14.
Sponsored by Ontario Clinical Oncology Group (OCOG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) — 2 open to participants now, 4 under way, 2 of them phase 3. Breast Neoplasms · Ontario Clinical Oncology Group (OCOG).
Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), this one is the 6th largest by planned enrollment of the 20 interventional ones that give a count, is the only one that started in 2023, is one of 5 in phase 3, and was the 23rd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →2 of the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG) are open now, in 2 countries. Recruiting first, the newest first:
Ontario Clinical Oncology Group (OCOG) · Sites in Australia, Canada
Ages 50+ · Women only
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 50 Years to 120 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 910 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 318 across the 20 interventional studies, 426 across the 4 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ontario Clinical Oncology Group (OCOG) is the lead sponsor of 56 studies on the registry; 4 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 24 studies in Breast Neoplasms by Ontario Clinical Oncology Group (OCOG), from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.
This is a randomized, two-arm, single blinded trial comparing two radiation treatment modalities, PBI and WBI. Following BCS or on the completion of additional adjuvant chemotherapy, eligible and consenting patients with newly diagnosed and histologically confirmed invasive carcinoma of the breast (without evidence of metastatic disease); with microscopically clear resection margins of 1mm (or no residual disease on re-excision) and negative axillary node involvement will be randomized in a 1:1 fashion to receive either PBI (experimental group) or WBI (control group). Study participants will receive 26Gy in 5 fractions in both treatment arms, treated once per day, for a period of 5-7 days. Study participants will not be made aware of treatment allocation to prevent any potential bias in their assessment of cosmesis. Stratification factors include tumour size, estrogen receptor (ER) status, and clinical centre.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For inclusion in this study, patients must fulfill all of the following criteria:
Exclusion Criteria:
Patients who satisfy any of the following exclusion criteria are NOT eligible for this study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
26 Gy in 5 fractions to the whole breast
Radiation: Whole Breast Irradiation (WBI)
26 Gy in 5 fractions to the tumour bed with a margin of normal tissue
Radiation: Partial Breast Irradiation (PBI)
The dose fractionation and prescription is 26Gy in 5 fractions to the PTV once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
The dose fractionation and prescription is 26Gy in 5 fractions to the PTV prescribed at the isocentre of the treatment fields treated once per day over 5-7 days (due to holiday weekends up to 8 days will be acceptable).
Local Recurrence
Time from randomization to any evidence of tumour recurrence (invasive and non-invasive) in the treated breast.
Time frame: Annually for 5 years post-randomization
Patient Assessment Cosmesis at 3 years
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System and the UK Patient Reported Outcomes Questions following BCS.
Time frame: 3 and 5 years post-randomization
Distant Disease Free Survival (DDSF)
Time from randomization to evidence of metastasis involving distant sites (e.g. bone, liver, lung, or brain).
Time frame: Annually for 5 years post-randomization.
Disease Free Survival (DFS)
Time from randomization to local recurrence, regional or distant recurrence, contralateral breast cancer, other second cancer, or death.
Time frame: Annually for 5 years post-randomization.
Overall Survival
Time from randomization to death of any cause.
Time frame: 3 years post-randomizaton.
Radiation Toxicity
Acute (2 weeks and up to 3 months after completing RT) and late toxicity (beyond the 3 months after completing RT) will be assessed by clinical centre personnel using the NCI CTCAE version 5.0.
Time frame: 2 weeks and 3 months post-radiation treatment, then annually for 5 years post-randomization.
Nurse/Clinical Research Associate assessed cosmesis at 3 and 5 years.
A nurse/Clinical Research Associate (CRA) assessment of cosmesis using the EORTC Breast Cosmetic Rating System. Nurses and CRAs will be training in assessing cosmesis using training slides and guide previously developed for other trials.
Time frame: 3 and 5 years post-randomization.
Patient Assessed Cosmesis at 5 years.
Cosmesis will be assessed by the patient using the Breast Cosmesis Questionnaire which incorporates the Modified EORTC Breast Cosmetic Rating System13,27,42 and the UK Patient Reported Outcomes Questions following BCS.
Time frame: 5 years post-randomization.
Patient Reported Quality of Life
Patients will complete the EORTC Breast Cancer Quality of life questionnaire
Time frame: 2 weeks post-radiation treatment, then at 3 and 5 years post-randomization.
Started Nov 2023 (actual). Primary completion is estimated for Nov 2029, 72 months after the start.
Of 328 non-industry phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 127. This study's planned 72 months is close to that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ontario Clinical Oncology Group (OCOG)